These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22328314)

  • 1. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
    Posch M; Maurer W; Bretz F
    Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive Dunnett tests for treatment selection.
    Koenig F; Brannath W; Bretz F; Posch M
    Stat Med; 2008 May; 27(10):1612-25. PubMed ID: 17876763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials.
    Wang SJ; James Hung HM; O'Neill RT
    Biom J; 2010 Dec; 52(6):798-810. PubMed ID: 21154897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On sample size determination in multi-armed confirmatory adaptive designs.
    Wassmer G
    J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adaptive confirmatory trial with interim treatment selection: practical experiences and unbalanced randomization.
    Heritier S; Lô SN; Morgan CC
    Stat Med; 2011 Jun; 30(13):1541-54. PubMed ID: 21432887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues in designing flexible trials.
    Posch M; Bauer P; Brannath W
    Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.
    Stallard N
    Stat Med; 2010 Apr; 29(9):959-71. PubMed ID: 20191605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive increase in sample size when interim results are promising: a practical guide with examples.
    Mehta CR; Pocock SJ
    Stat Med; 2011 Dec; 30(28):3267-84. PubMed ID: 22105690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive dose-finding: Proof of concept with type I error control.
    Miller F
    Biom J; 2010 Oct; 52(5):577-89. PubMed ID: 20976691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.